Supplements · Metabolic & Cardiometabolic
moderate coffee intake decreases cardiovascular disease risk
In plain terms: Does moderate coffee (2-5 cups/day) lower heart-disease risk?
Yes — across many large meta-analyses, moderate coffee (about 2-5 cups/day) is associated with lower cardiovascular and all-cause mortality in a U-shaped curve; it does not raise heart-disease risk at these intakes.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
The evidence (15)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Ding 2025 · Front Nutr | meta-analysis | supports | moderate | In people with diabetes, coffee consumption was associated with lower CVD and all-cause mortality. |
| Crippa 2014 · Am J Epidemiol | meta-analysis | supports | high | Nonlinear meta-analysis showed largest reductions at ~4 cups/day for all-cause (16%) and ~3 cups/day for CVD mortality (21%). |
| Ding Y et al 2026 · study_type: observational | observational | supports | high | UK Biobank cohort (n=167,142): unsweetened coffee showed a U-shaped dose-response with incident CVD (P-nonlinearity<0.001), lowest risk at 2.5 units/day; HRs ranged 0.81-0.90 for 0-5 units/day but null at >5 units/day (HR 1.00). Sweetened c |
| Ribeiro 2020 · Nutr Metab Cardiovasc Dis | meta-analysis | supports | moderate | After myocardial infarction, coffee consumption was associated with lower cardiovascular and all-cause mortality, indicating safety and benefit. |
| Mostofsky 2012 · Circ Heart Fail | meta-analysis | supports | moderate | Moderate coffee intake associated with lower incident heart failure risk in a U-shaped dose-response. |
| Steffen 2012 · J Hypertens | meta-analysis | mixed | moderate | Long-term coffee did not clearly raise blood pressure or hypertension risk, tempering but not supporting a strong protective claim. |
| D'Elia 2019 · Eur J Nutr | meta-analysis | mixed | moderate | Dose-response meta-analysis found an inverse association between habitual coffee and hypertension risk only at higher intakes, weak at moderate doses. |
| Di Maso 2021 · Adv Nutr | meta-analysis | supports | high | Pooled cohorts showed coffee inversely associated with CVD, with greatest benefit at 3-4 cups/day and none thereafter. |
| Kim 2019 · Eur J Epidemiol | meta-analysis | supports | high | 40-study meta-analysis found lowest CVD mortality risk at ~2.5 cups/day and all-cause at 3.5 cups/day. |
| Alves M et al 2026 · study_type: observational | observational | mixed | low | NHANES cross-sectional analysis of 915 heart-failure patients: 1-3 cups/day showed no significant mortality association, but ≥4 cups/day was associated with increased all-cause mortality (OR 1.58, 95% CI 1.16-2.16). |
| Ding 2014 · Circulation | meta-analysis | supports | high | Dose-response meta-analysis found moderate coffee (3-5 cups/day) associated with lowest CVD risk in a U-shaped relationship. |
| Haghighatdoost 2023 · Nutrients | meta-analysis | mixed | moderate | Coffee showed no overall increased hypertension risk and possible protection at higher intake, though findings were heterogeneous. |
| Grosso 2016 · Eur J Epidemiol | meta-analysis | supports | high | Consumption up to 4 cups/day linked to decreased all-cause and CVD mortality, robust across smoking strata. |
| Biswas S et al 2026 · study_type: meta-analysis | meta-analysis | supports | moderate | Dose-response meta-analysis of 13 prospective cohorts (656,666 participants) found moderate coffee consumption (2-4 cups/day) associated with reduced heart-failure risk (HR 0.925, 95% CI 0.882-0.971); a J-shaped pattern was suggested (nonli |
| Shahinfar 2021 · Nutr Metab Cardiovasc Dis | meta-analysis | supports | moderate | Dose-response meta-analysis in type 2 diabetes found coffee associated with reduced CVD events and mortality. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.